|Application ||WB, LCI|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||109881 Da|
|Homology||Rat, human - identical.|
|Other Names||Ephrin type-B receptor 1, Ephb1|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)RSQTNTARIDGLR, corresponding to amino acid residues 485- 497 of mouse EphB1 (Accession Q8CBF3). Extracellular, N-terminus.|
|Peptide Confirmation||Confirmed by mass-spectrography and amino acid analysis.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||25 µl, 50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.8 mg/ml.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl DDW.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
|Formulation||Lyophilized powder. Resuspended antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Eph receptors are the largest family of receptor tyrosine kinases (RTKs). EphA receptors (EphA1-10) bind ephrinA ligands which are GPI-linked proteins and EphB receptors (EphB1-6) bind ephrinB ligands which are membrane protein with one transmembrane domain1,2. Within each subfamily, interactions between receptor and ligand are promiscuous. In addition, Eph receptors can also bind ephrins from the other class2. Forward and reverse signaling through Eph receptors is a unique characteristic to this RTK since ephrins are physically linked to the plasma membrane3. Structurally, Eph receptors contain an extracellular ligand-binding domain, a transmembrane domain and an intracellular C-terminal domain responsible for intracellular signaling1. Forward Eph receptor signaling involves autophosphorylation of the receptor via a tyrosine kinase domain, as well as phosphorylation of other proteins. Known effectors of the forward signaling include Src kinase and Ras/Rho GTPases2. Much less is known about the reverse signaling mediated by Eph receptors. Besides from acting independently, Eph receptors can also signal in concert with other receptors. For example, Eph receptors cooperate with FGF receptor, NMDA ligand-gated ion channel and chemokine G-protein coupled receptor2. Biological activities attributed to the Eph receptor-ephrin signaling module include establishing neuronal connections, mediating neuronal plasticity and repair following neuronal injury2,4. Eph receptors may also have a role in the immune system5. Eph receptors are expressed in the developing nervous system, and in the adult brain. It is also detected in the pancreas, intestine, bone and lymphocytes. In cancer cells, Eph receptors and ephrins are overexpressed2,6,7. They are also implicated in neurodegenerative disorders like Alzheimer’s disease1.
References 1. Chen, Y. et al. (2012) Cell. Signal. 24, 606. 2. Pasquale, E.B. (2008) Cell 133, 38. 3. Pasquale, E.B. (2005) Mol. Cell Biol. 6, 462. 4. Du, J. et al. (2007) Curr. Pharm. Des. 13, 2507. 5. Wu, J. and Luo, H. (2005) Curr. Opin. Hematol. 12, 292. 6. Ireton, R.C. and Chen, J. (2005) Curr. Cancer Drug Targets 5, 149. 7. Noren, N.K. and Pasquale, E.B. (2007) Cancer Res. 67, 3994.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.